Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.
Michael CecchiniJanie Y ZhangWei WeiJeffrey S SklarJill LacyMinghao ZhongYong KongHongyu ZhaoJassim DiPalermoLesley DevineStacey M SteinJeremy KortmanskyKimberly L JohungRanjit S BindraPatricia M LoRussoKurt A SchalperPublished in: Cancer research communications (2023)
in tumors with MGMT silencing. Up to 40% of colorectal cancer is MGMT promoter hypermethylated, and we investigated whether TMZ and olaparib are effective in this population. We also measured MGMT by QIF and observed efficacy only in patients with low MGMT, suggesting quantitative MGMT biomarkers more accurately predict benefit to alkylator combinations.